Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Isolated <i>KRAS</i> and <i>NRAS</i> mutations in adults with monocytosis and/or cytopenia(s).

Haematologica·2025
Same author

Molecular Characterization of <italic>MECOM</italic> Rearrangements in Two Cases with Myelodysplastic Syndrome and t(2;3)(p23;q26.2).

Cytogenetic and genome research·2025
Same author

Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly.

Cancer·2025
Same author

Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology Group.

American journal of hematology·2025

Related Experiment Video

Updated: Oct 1, 2025

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.4K

How I Diagnose Primary Myelofibrosis.

Sonam Prakash1, Attilio Orazi2

  • 1Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.

American Journal of Clinical Pathology
|March 3, 2022
PubMed
Summary

Diagnosing primary myelofibrosis (PMF) is complex due to overlaps with other conditions. Integrating clinical, morphological, and molecular data is crucial for accurate PMF diagnosis and appropriate treatment.

Keywords:
Autoimmune myelofibrosisMyelodysplastic syndrome with associated fibrosisMyeloproliferative neoplasmPrimary myelofibrosis

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.8K
Isolation of CD 90+ Fibroblast/Myofibroblasts from Human Frozen Gastrointestinal Specimens
06:02

Isolation of CD 90+ Fibroblast/Myofibroblasts from Human Frozen Gastrointestinal Specimens

Published on: January 31, 2016

9.7K

Related Experiment Videos

Last Updated: Oct 1, 2025

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.4K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.8K
Isolation of CD 90+ Fibroblast/Myofibroblasts from Human Frozen Gastrointestinal Specimens
06:02

Isolation of CD 90+ Fibroblast/Myofibroblasts from Human Frozen Gastrointestinal Specimens

Published on: January 31, 2016

9.7K

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Primary myelofibrosis (PMF) is a BCR/ABL1-negative myeloproliferative neoplasm (MPN).
  • PMF presents with shorter survival and higher leukemic transformation risk compared to other MPNs.
  • PMF diagnosis is challenging due to overlapping features with other myeloid neoplasms and reactive conditions.

Purpose of the Study:

  • To summarize and discuss key features for diagnosing PMF.
  • To differentiate PMF from myelodysplastic syndrome with fibrosis and autoimmune myelofibrosis.
  • To highlight the importance of integrating diverse diagnostic findings.

Main Methods:

  • Case-based approach summarizing clinical, morphological, and molecular features.
  • Discussion of diagnostic criteria for PMF in prefibrotic and fibrotic stages.
  • Review of genetic mutations (JAK2, CALR, MPL) and next-generation sequencing in diagnosis.

Main Results:

  • PMF involves abnormal megakaryocyte and granulocyte proliferation in bone marrow.
  • Driver mutations (JAK2, CALR, MPL) are present in ~90% of PMF cases.
  • Cytogenetic abnormalities and somatic mutations aid diagnosis in triple-negative PMF.

Conclusions:

  • Accurate diagnosis of PMF is essential due to significant differences in prognosis and treatment.
  • Integration of clinical, morphological, and molecular/genetic findings is critical.
  • Distinguishing PMF from other myelofibrotic conditions requires a comprehensive approach.